Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 3 | 4.111 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS00941Q2030 AIRNET... ► Artikel lesen | |
03.01. | BIMI International Medical Inc. - 8-K, Current Report | 1 | SEC Filings | ||
19.12.23 | BIMI International Medical reports Q3 results | 4 | Seeking Alpha | ||
19.12.23 | BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results | 213 | GlobeNewswire (Europe) | NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine... ► Artikel lesen | |
19.12.23 | BIMI International Medical Inc. - 8-K, Current Report | 2 | SEC Filings | ||
19.12.23 | BIMI International Medical Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
04.12.23 | BIMI International Medical Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.11.23 | BIMI International Medical Inc.: BIMI Announces Buyback of Warrants | 2 | GlobeNewswire (USA) | ||
27.11.23 | BIMI International Medical Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.11.23 | BIMI International Medical Inc.: BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c) | 175 | GlobeNewswire (Europe) | NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company") today announced that on November 21, 2023, the Company received a notification letter from The Nasdaq Stock... ► Artikel lesen | |
27.11.23 | BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results | 170 | GlobeNewswire (Europe) | NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended... ► Artikel lesen | |
22.11.23 | BIMI International Medical Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.11.23 | BIMI International Medical Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
08.11.23 | BIMI International Medical Inc. - 8-K, Current Report | 3 | SEC Filings | ||
08.11.23 | BIMI International Medical Inc.: BIMI Announces Subsidiary Phenix Bio Inc.'s New Product Launch | 1 | GlobeNewswire (USA) | ||
30.10.23 | BIMI International Medical Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.10.23 | BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor | 2 | GlobeNewswire (USA) | ||
30.10.23 | BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Mainland China Non-Exclusive Distributor | 1 | GlobeNewswire (USA) | ||
24.08.23 | BIMI International Medical Inc.: BIMI Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c) | 307 | GlobeNewswire (Europe) | NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company") today announced that on August 22, 2023, the Company received a notification letter from The Nasdaq Stock... ► Artikel lesen | |
07.08.23 | BIMI International Medical Inc. Announces Strategic Partnership by its Phenix Bio Inc. Subsidiary with China Duty Free Group | 339 | GlobeNewswire (Europe) | NEW YORK, NY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a leading global provider of healthcare services and innovative medical solutions, today announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 27,280 | -0,15 % | JPMORGAN stuft Fresenius SE auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Fresenius auf "Neutral" mit einem Kursziel von 32,50 Euro belassen. Die am 8. Mai anstehenden Quartalszahlen sollten einen ordentlichen Jahresstart... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 38,620 | -0,87 % | FMC: Erfolge werden deutlicher | Fresenius Medical Care (FMC) erwirtschaftet derzeit rund 70 Prozent des Umsatzes in den USA. Dabei ist das dortige Geschäft überdurchschnittlich profitabel für FMC. Sollte es in dem Land zu Steuersenkungen... ► Artikel lesen | |
GERRESHEIMER | 100,30 | -1,08 % | Gerresheimer wieder dreistellig - Jefferies hebt den Daumen | Zum Wochenauftakt geht es für die Gerresheimer-Aktie um zwei Prozent nach oben. Nach einem leichtem Rücksetzer notieren die Scheine damit wieder über 100 Euro. Grund für den Aufschlag ist ein positiver... ► Artikel lesen | |
UNITEDHEALTH | 454,50 | -0,23 % | UnitedHealth Aktie: Robustes Quartalsergebnis 2024 | UnitedHealth Group (NYSE:UNH), der größte Krankenversicherer der USA, lieferte ein überzeugenderes Quartalsergebnis für das erste Quartal 2024 als erwartet und übertraf dabei sowohl die Gewinn- als... ► Artikel lesen | |
STRATEC | 41,900 | +0,96 % | Minimale Kursveränderung bei Stratec-Aktie (40,00 €) | Der Kurs der dem Anteilsschein von Stratec kommt kaum von der Stelle. Zuletzt zahlten Investoren für das Wertpapier 40,00 Euro. Einen minimalen Wertverlust von 0,12 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
BIOTEST | 29,200 | +0,69 % | Biotest baut aus, während Grifols weiter mit Gotham-Schatten kämpft. Ist die Mutter die spannendere Aktie? | Biotest hat in Wuppertal das 12. Plasmasammel-zentrum in Deutschland offiziell eröffnet. Klares Wachstumsprogramm ganz nach den Wünschen der Hauptaktionärin Grifols, die zuletzt von Shortsellern unter... ► Artikel lesen | |
PLUS THERAPEUTICS | 1,592 | +5,15 % | Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense | ||
ATOSSA THERAPEUTICS | 1,446 | +2,70 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
MOBILE-HEALTH NETWORK SOLUTIONS | 23,880 | 0,00 % | APAC Telehealth Leader MNDR Expects Revenue Growth in H12024 vs H12023 | SINGAPORE, April 22, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) ("Mobile-Health" or the "Company"), a pioneering Asia-Pacific ("APAC") telehealth provider, today provided... ► Artikel lesen | |
PROGYNY | 32,600 | +0,62 % | Progyny, Inc. Announces Third Quarter 2023 Results | Record Quarterly Revenue of $280.9 Million, Reflecting 37% Growth Over the Prior Year PeriodRaises Full Year Revenue and Earnings GuidanceStrong Sales Season Produces 1.3 Million New Covered Lives... ► Artikel lesen | |
PRIVIA HEALTH GROUP | 18,170 | -3,35 % | Where Privia Health Gr Stands With Analysts | ||
PROCEPT BIOROBOTICS | 52,48 | -2,36 % | PROCEPT BioRobotics Corp - 8-K, Current Report | ||
ATRICURE | 23,050 | -0,52 % | AtriCure upgraded at Oppenheimer on valuation | ||
RXSIGHT | 52,84 | -3,79 % | RxSight, Inc. - 8-K, Current Report |